Imatinib indications

Imatinibis aBCR-ABLtyrosine kinase inhibitor.

Indications are as follows:

1.Adult and pediatric patients newly diagnosed with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML).

2.Philadelphia chromosome-positive chronic myelogenous leukemia(Ph+ CML)Patients in blast crisis (BC), accelerated phase (AP) or chronic phase after failure of interferon-α treatment.

3.Adult patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+ ALL).

4.Adult patients with myelodysplasia/myeloproliferative disease(MDS/MPD)PDGFR (Platelet Derived Growth Factor Receptor)gene rearrangement was determined by a FDA approved test.

5.Adult patients with aggressive systemic mastocytosis(ASM) who have been determined by an FDA-approved test to be free ofD816V c-Kitmutation, or c-Kit mutation status unknown.

6.Adult patients with hypereosinophilic syndrome(HES) or chronic eosinophilic leukemia(CEL) who haveFIP1L1-PDGFRα Fusion Kinase(CHIC2Mutation analysis of allelic loss or FISHProof) span>and patients withHES or CEL whoseFIP1L1-PDGFRalpha fusion kinase is negative or unknown.

7.Adult patients with unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP). IndiaNATCOPharmaceutical retail price100mg120 tablets is about 400. IndiaCiplaPharmaceutical retail price per box100mg10 capsules40yuan. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.